![Frank Kalkbrenner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Frank Kalkbrenner
Director/Board Member at
Acousia Therapeutics GmbH
Profile
Frank Kalkbrenner is currently a Director at STAT-Dx Life SL, Amal Therapeutics SA, Acousia Therapeutics GmbH, eTheRNA immunotherapies NV, Aelin Therapeutics NV, T3 Pharmaceuticals AG, Rinri Therapeutics Ltd., and a Member-Supervisory Board at Hookipa Biotech AG.
He was previously a Director at Eyevensys SAS and Cardior Pharmaceuticals GmbH.
Frank Kalkbrenner active positions
| Companies | Position | Start |
|---|---|---|
Boehringer Ingelheim (Venture Capital)
 Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm focuses on companies operating in groundbreaking innovation including cancer, auto-immunity indications, digital solutions, infectious disease and regenerative medicine services. It provides financing for seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes board seat. | Private Equity Investor | 2010-06-30 |
Acousia Therapeutics GmbH
 Acousia Therapeutics GmbH BiotechnologyHealth Technology Develops drugs for local application | Director/Board Member | - |
STAT-Dx Life SL
 STAT-Dx Life SL Medical SpecialtiesHealth Technology Develops molecular and immunoassay diagnostic systems for clinical decentralized testing | Director/Board Member | - |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Operates a proprietary cell penetrating peptide platform which develops therapeutic vaccines in oncology | Director/Board Member | - |
T3 Pharmaceuticals AG
 T3 Pharmaceuticals AG BiotechnologyHealth Technology Develops bacterial cancer therapies and medicines | Director/Board Member | - |
Rinri Therapeutics Ltd.
 Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops regenerative stem cell-based therapies for treatment of hearing loss | Director/Board Member | - |
eTheRNA immunotherapies NV
 eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Director/Board Member | - |
Aelin Therapeutics NV
 Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops drugs for antibiotics and first-in-class therapeutics | Director/Board Member | - |
Former positions of Frank Kalkbrenner
| Companies | Position | End |
|---|---|---|
Hookipa Biotech AG
 Hookipa Biotech AG Medical SpecialtiesHealth Technology Develops new generation prophylactic and therapeutic vaccines | Director/Board Member | 2024-11-17 |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
81
1st degree connections
11
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 11 |
|---|---|
Boehringer Ingelheim (Venture Capital)
Boehringer Ingelheim (Venture Capital) Investment ManagersFinance BIVF invests in companies located across the globe including the United States, Europe and China. The firm focuses on companies operating in groundbreaking innovation including cancer, auto-immunity indications, digital solutions, infectious disease and regenerative medicine services. It provides financing for seed and early stage capital requirements. The firm acquires minority interest and makes follow-on investments. It also takes board seat. | Finance |
STAT-Dx Life SL
STAT-Dx Life SL Medical SpecialtiesHealth Technology Develops molecular and immunoassay diagnostic systems for clinical decentralized testing | Health Technology |
Hookipa Biotech AG
Hookipa Biotech AG Medical SpecialtiesHealth Technology Develops new generation prophylactic and therapeutic vaccines | Health Technology |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Commercial Services |
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Operates a proprietary cell penetrating peptide platform which develops therapeutic vaccines in oncology | Health Technology |
Acousia Therapeutics GmbH
Acousia Therapeutics GmbH BiotechnologyHealth Technology Develops drugs for local application | Health Technology |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology Operates as a technology platform that develops mRNA and lipid nanoparticle therapeutics | Health Technology |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Health Technology |
Aelin Therapeutics NV
Aelin Therapeutics NV Pharmaceuticals: MajorHealth Technology Develops drugs for antibiotics and first-in-class therapeutics | Health Technology |
T3 Pharmaceuticals AG
T3 Pharmaceuticals AG BiotechnologyHealth Technology Develops bacterial cancer therapies and medicines | Health Technology |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops regenerative stem cell-based therapies for treatment of hearing loss | Commercial Services |
- Stock Market
- Insiders
- Frank Kalkbrenner
